Keensight Capital, a private equity manager dedicated to pan-European growth buyout investments, has acquired a majority stake in BYG4lab, an independent provider of data management software for medical laboratories specialised in both biology and microbiology.
Keensight Capital will invest alongside the management team and IRDI Capital Investissement.
Founded in 1982 and headquartered in France, BYG4lab develops software that enhances the efficiency of a laboratory. The Company provides a number of key benefits, including but not limited to: improving workflow management, making instrument integration more efficient, handling mega lab configuration, designing personalised dashboards, maximising automatic validation, and managing quality control.
The Company addresses both Central Lab and Point of Care testing, as well as all disciplines in the field of medical biology – immunochemistry, haematology, molecular, microbiology, and, amongst others – serving 4,500+ individual laboratories, including some of the large, major European players.
